We have investigated the financial costs of attempts to optimise blood pressure control in patients referred to our blood pressure clinic. At first referral, the average blood pressure in the 262 patients studied were 167/97 mmHg and the monthly costs of the antihypertensive drugs was £23.44. After 1 year of clinic attendance, the blood pressure was reduced to 149/87 mmHg, and the average drug costs had risen to £30.68. For drug expenditure alone, the cost of reducing systolic blood pressure by 1 mmHg was £0.36p (Euro 0.55, USD 0.55) and for diastolic blood pressure the cost-was £0.72p (Euro 1.12, USD 1.13).
Introduction
A great many population studies have demonstrated that only a small minority of hypertensive patients have adequate control of their blood pressure. 1 This figure is substantially worsened with more recent recommendations, on the basis of the Hypertension Optimal Treatment (HOT) study, that pressures should be reduced to below 140/80 mmHg. 2 The British Hypertension Society (BHS) 1993 guidelines suggested that the target blood pressure should be below 160/ 90 mmHg. 3 In the 1999 BHS guidelines, this figure was reduced to 140/85 and 140/80 mmHg in diabetics. 4, 5 If this target is to be achieved, patients will need to take more antihypertensive drugs with a resulting increase in costs. 6 In severe, resistant hypertension these costs are likely to be high with newer drugs in triple therapy regimes. We have examined the drug costs in patients referred to our hospital's hypertension clinic, mainly for resistant hypertension, in relation to the change in blood pressure achieved, in order to estimate the cost per mmHg reduction.
Methods
The records of all patients referred to the clinic during 1999 were examined. The financial cost of the drug regime on first referral (ie that instigated by the general practitioner) and the costs 1 year later, or at the last visit if less than one year later, were calculated from the British National Formulary (September 1999).
In the clinic, all blood pressure were measured with the OMRON HEM 705 CP monitor. The first reading at each visit was discarded and the mean of all subsequent recordings (two or more) were calculated.
The blood pressure clinic was staffed by one permanent senior clinician, one rotating junior clinician and one senior clinical nurse specialist with a special interest in hypertension. Patients were referred to the clinic by their general practitioners for a variety of reasons, so no formal protocol was feasible in the choice of antihypertensive drugs. However, the choice of drugs was based on the Birmingham Hypertension Square with a preference for calcium channel blockers or thiazide diuretics in older patients and those of African origin. 7 Angiotensin-converting enzymes (ACE) inhibitors or angiotensin-receptor blockers (ARBs) were given to most diabetics, younger patients and those with evidence of heart failure or renal impairment.
The target blood pressure employed in the clinic were nearer to those in the BHS 1999 guidelines, although these were not published until September of that year when this study was nearing completion.
Results
During 1999, 452 patients were referred to the clinic, but we were unable to locate the records in 50 of them. Of the 402 remaining patients, 27 received no medication, 67 attended only once and in 46 there was insufficient information. This left 262 patients who were included in the study.
At the first visit, 6% of patients were on no medication, 34% were receiving monotherapy and 75% on combination therapies ( Table 1 ). The mean financial cost of the regimen at the first visit was d23.44p for 28 days and the cost 1 year later was d30.68p, an increase of d7.24p. In 75 patients drug costs were reduced, in 47 there was no change while in the remaining 142 there was an increase. During this time, the blood pressure fell from an average of 167/97 to 149/87 mmHg. Thus, the monthly cost of a reduction of systolic pressure by 1 mmHg was d0.36p (Euro 0.56, US$ 0.55c) and for a reduction of diastolic pressure by 1 mmHg the cost was d0.72p (Euro 1.12, US$ 1.13).
Discussion
This study only takes into account changes in drug costs and did not measure other costs including investigations, number of consultations and staff salaries, which amount to about 30% of all costs. 8 Thus, our data are relevant to the cost of increased treatment that would occur if the patient had been managed in primary care alone. The main sources of error are the blood pressure measurements which may have been affected by the phenomenon of regression towards the norm, and anxiety particularly at the first visit. None of the patients were newly diagnosed so any pressor effect of diagnosis can be excluded. We have previously found no evidence that outpatient blood pressure recordings are on average any higher than those obtained in general practice. 9 If some of the blood pressure fall is explained by regression to the norm, then our financial estimates are slightly greater than that might be seen in general practice.
Estimates of the financial cost of blood pressure reduction vary depending on the selection of patients. The treatment of hypertension in general, rather than resistant patients, has been calculated as around d120 per year (d10 per month) by 1991 prices. 8 However, that study was conducted before the lower target blood pressures were introduced, whereas our study was conducted after publication of the HOT study. 2 The financial cost of blood pressure reduction, which reduces stroke by 40%, must be seen in the light of the costs of stroke by the United Kingdom economy amounting to 2.3 dBn/year and the finding that 10.5% of strokes are associated with untreated hypertension and 38.3% associated with treated but uncontrolled hypertension. 10 
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